JP2019511496A5 - - Google Patents

Download PDF

Info

Publication number
JP2019511496A5
JP2019511496A5 JP2018548363A JP2018548363A JP2019511496A5 JP 2019511496 A5 JP2019511496 A5 JP 2019511496A5 JP 2018548363 A JP2018548363 A JP 2018548363A JP 2018548363 A JP2018548363 A JP 2018548363A JP 2019511496 A5 JP2019511496 A5 JP 2019511496A5
Authority
JP
Japan
Prior art keywords
dose
salt
administered
day
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018548363A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511496A (ja
JP7224916B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/022551 external-priority patent/WO2017161016A1/en
Publication of JP2019511496A publication Critical patent/JP2019511496A/ja
Publication of JP2019511496A5 publication Critical patent/JP2019511496A5/ja
Priority to JP2022125186A priority Critical patent/JP7322259B2/ja
Application granted granted Critical
Publication of JP7224916B2 publication Critical patent/JP7224916B2/ja
Priority to JP2023121182A priority patent/JP2023139211A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018548363A 2016-03-16 2017-03-15 真菌感染の処置のための投薬レジメン Active JP7224916B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022125186A JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン
JP2023121182A JP2023139211A (ja) 2016-03-16 2023-07-26 真菌感染の処置のための投薬レジメン

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201662309211P 2016-03-16 2016-03-16
US62/309,211 2016-03-16
US201662350591P 2016-06-15 2016-06-15
US62/350,591 2016-06-15
US201662415928P 2016-11-01 2016-11-01
US62/415,928 2016-11-01
US201662418727P 2016-11-07 2016-11-07
US62/418,727 2016-11-07
US201662419076P 2016-11-08 2016-11-08
US62/419,076 2016-11-08
US201662436716P 2016-12-20 2016-12-20
US62/436,716 2016-12-20
PCT/US2017/022551 WO2017161016A1 (en) 2016-03-16 2017-03-15 Dosing regimens for treatment of fungal infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022125186A Division JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン

Publications (3)

Publication Number Publication Date
JP2019511496A JP2019511496A (ja) 2019-04-25
JP2019511496A5 true JP2019511496A5 (https=) 2020-05-07
JP7224916B2 JP7224916B2 (ja) 2023-02-20

Family

ID=59850952

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018548363A Active JP7224916B2 (ja) 2016-03-16 2017-03-15 真菌感染の処置のための投薬レジメン
JP2022125186A Active JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン
JP2023121182A Pending JP2023139211A (ja) 2016-03-16 2023-07-26 真菌感染の処置のための投薬レジメン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022125186A Active JP7322259B2 (ja) 2016-03-16 2022-08-05 真菌感染の処置のための投薬レジメン
JP2023121182A Pending JP2023139211A (ja) 2016-03-16 2023-07-26 真菌感染の処置のための投薬レジメン

Country Status (8)

Country Link
US (2) US11712459B2 (https=)
EP (2) EP4268896A3 (https=)
JP (3) JP7224916B2 (https=)
CN (1) CN109154603A (https=)
CA (1) CA3017485A1 (https=)
ES (1) ES2955711T3 (https=)
MA (1) MA43825A (https=)
WO (1) WO2017161016A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2645074T3 (es) 2011-03-03 2017-12-04 Cidara Therapeutics, Inc. Agentes antifúngicos y sus usos
RU2639483C2 (ru) 2012-03-19 2017-12-21 Сидара Терапьютикс, Инк. Режимы дозирования для соединений класса эхинокандинов
CN108883152A (zh) 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
WO2017161016A1 (en) 2016-03-16 2017-09-21 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
US11197909B2 (en) 2017-07-12 2021-12-14 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
CA3103619A1 (en) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent
WO2020086931A1 (en) 2018-10-25 2020-04-30 Cidara Therapeutics, Inc. Polymorph of echinocandin antifungal agent
BR112021022876A2 (pt) * 2019-05-16 2022-04-12 Scynexis Inc Método para descolonizar candida auris de uma área anatômica de um sujeito

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427660A (en) 1982-03-03 1984-01-24 Research Corporation Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections
US5166135A (en) 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
US6030944A (en) 1991-10-01 2000-02-29 Merck & Co., Inc. Cyclohexapeptidyl bisamine compounds
US5399552A (en) 1991-10-17 1995-03-21 Merck & Co, Inc Antibiotic peptides bearing aminoalkylthioether moieties
US5378804A (en) 1993-03-16 1995-01-03 Merck & Co., Inc. Aza cyclohexapeptide compounds
US6268338B1 (en) 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
US5948753A (en) 1993-05-04 1999-09-07 Merck & Co., Inc. Cyclohexapeptidyl propanolamine compounds
CA2161149A1 (en) 1993-05-04 1994-11-10 James M. Balkovec Cyclohexapeptidyl aminoalkyl ethers
US5541160A (en) 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
US5514651A (en) 1994-09-16 1996-05-07 Merck & Co., Inc. Aza cyclohexapeptide compounds
US5516756A (en) 1994-10-31 1996-05-14 Merck & Co., Inc. Aza cyclohexapeptide compounds
WO1996022784A1 (en) 1995-01-26 1996-08-01 Merck & Co., Inc. Novel antifungal cyclohexapeptides
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
AR006598A1 (es) 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
USRE38984E1 (en) 1996-09-12 2006-02-14 Merck & Co., Inc. Antifungal combination therapy
DE69933046T2 (de) 1998-12-09 2007-09-13 Eli Lilly And Co., Indianapolis Reinigung von echinocandin cyclopeptiden
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1582204B1 (en) 1999-03-03 2013-09-25 Eli Lilly & Company Echinocandin pharmaceutical formulations containing micelle-forming surfactants
WO2000051567A1 (en) 1999-03-03 2000-09-08 Eli Lilly And Company Processes for making pharmaceutical oral ecb formulations and compositions
US6309622B1 (en) * 1999-03-26 2001-10-30 Protech Professional Products, Inc. Antimicrobial denture cleansing compositions
WO2000062776A1 (en) * 1999-04-16 2000-10-26 Fujisawa Pharmaceutical Co., Ltd. Antifungal compositions
HU0104790D0 (en) 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
AU2003304398A1 (en) 2002-10-16 2005-02-25 Board Of Regents, The University Of Texas System Methods and compositions for increasing the efficacy of biologically-active ingredients
US6913759B2 (en) 2003-03-11 2005-07-05 Curatek Pharmaceuticals Holding, Inc. Gel composition and method for treatment of vaginal infections
DE602004010915T2 (de) 2003-07-22 2008-12-11 Theravance, Inc., South San Francisco Verwendung eines antimykotischen echinocandin-mittels in kombination mit einem antibakteriellen glycopeptid-mittel
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
JP5319281B2 (ja) 2005-07-26 2013-10-16 ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー エキノカンジン系薬物に対する耐性の分析法並びに同分析法のためのオリゴヌクレオチド・セット及び試薬キット
WO2007113386A1 (en) 2006-03-31 2007-10-11 Karyon-Ctt Ltd Peptide conjugates
GB0702020D0 (en) 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20090238867A1 (en) 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
US20100009009A1 (en) 2008-07-10 2010-01-14 Micropure, Inc. Method and composition for prevention and treatment of oral fungal infections
GB0817121D0 (en) 2008-09-18 2008-10-29 Univ St Andrews Anti-fungal therapy
PT2400951T (pt) 2009-02-25 2018-11-26 Mayne Pharma Llc Composições de espuma tópica
CN102421790A (zh) 2009-05-07 2012-04-18 帝斯曼知识产权资产管理有限公司 制备环肽的方法
NO2470168T3 (https=) 2009-08-26 2018-06-30
EP2470190A4 (en) 2009-08-27 2013-07-17 Seachaid Pharmaceuticals Inc ECHINOCANDINDERIVATE
US9561285B2 (en) 2010-01-22 2017-02-07 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
ES2645074T3 (es) 2011-03-03 2017-12-04 Cidara Therapeutics, Inc. Agentes antifúngicos y sus usos
WO2013017691A1 (en) 2011-08-04 2013-02-07 Medizinische Universität Innsbruck Cahgt1p inhibitors for use in the treatment of candidiasis
US8829053B2 (en) 2011-12-07 2014-09-09 Rochal Industries Llp Biocidal compositions and methods of using the same
RU2639483C2 (ru) 2012-03-19 2017-12-21 Сидара Терапьютикс, Инк. Режимы дозирования для соединений класса эхинокандинов
CN102766198A (zh) 2012-05-04 2012-11-07 中国人民解放军第二军医大学 一种糖肽类抗真菌化合物及其制备方法与应用
WO2014113693A1 (en) 2013-01-18 2014-07-24 University Of Utah Research Foundation Modified release osmotic pump for ph-responsive intravaginal drug delivery
WO2014124504A1 (en) 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions and methods for treating biofilms
EP2968381A4 (en) 2013-03-15 2016-11-30 Sidney Hecht Sugar-linker-drug conjugates
NZ713615A (en) 2013-05-01 2020-05-29 Neoculi Pty Ltd Methods for treating bacterial infections
US20160213742A1 (en) 2013-09-04 2016-07-28 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2017049105A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Formulations for treating fungal infections
WO2017049102A1 (en) 2015-09-16 2017-03-23 Cidara Therapeutics, Inc. Methods for treating fungal infections
CN108883152A (zh) 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
WO2017161016A1 (en) 2016-03-16 2017-09-21 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
WO2018085200A1 (en) 2016-11-01 2018-05-11 Cidara Therapeutics, Inc. Single dose methods for preventing and treating fungal infections
US20210002346A1 (en) 2016-11-29 2021-01-07 Cidara Therapeutics, Inc Methods for preventing fungal infections
CN110753698A (zh) 2017-01-31 2020-02-04 奇达拉治疗公司 用于治疗真菌感染的方法
WO2018187574A1 (en) 2017-04-05 2018-10-11 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2018191692A1 (en) 2017-04-14 2018-10-18 Cidara Therapeutics, Inc. Methods for treating fungal infections
US11197909B2 (en) 2017-07-12 2021-12-14 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
WO2019027498A1 (en) 2017-08-03 2019-02-07 Cidara Therapeutics, Inc. METHOD FOR PREVENTING AND TREATING INTRA-ABDOMINAL CANDIDOSIS
CA3103619A1 (en) 2018-06-15 2019-12-19 Cidara Therapeutics, Inc. Synthesis of echinocandin antifungal agent

Similar Documents

Publication Publication Date Title
JP2019511496A5 (https=)
JP2012131811A5 (https=)
JP2017503820A5 (https=)
HK1198869A1 (en) Combination treatments for hepatitis c
CA3019769C (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2015523355A5 (https=)
JP2006504795A5 (https=)
JP2012530723A5 (https=)
JP2013500977A5 (https=)
JP2012502047A5 (https=)
JP2013541583A5 (https=)
JP2018509388A5 (https=)
JP2012525391A5 (https=)
JP2017519762A5 (https=)
JP2013540734A5 (https=)
JP2016512247A5 (https=)
JP2016505050A5 (https=)
JP2012520665A5 (https=)
JP2015514093A5 (https=)
JP2016501208A5 (https=)
CN103735570A (zh) 一种预防口腔真菌感染的口腔护理液
CN107714678A (zh) 紫檀芪在制备mcr‑1酶抑制剂中的应用
Bamba et al. A case of vocal cord cyst with cryptococcal infection
CN107920994A (zh) 用于治疗目的的板层小体的组合物和方法
JP2013542262A5 (https=)